BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

TEACHER

Chia-Jui Su

Session 10 – AI & Digital Health

Date:28 July (Thursday)
Time:  15:40 – 17:10 (GMT+8)

Chia-Jui Su

Co-Head of Healthcare & Life Science
KPMG in Taiwan

Dr Su is a senior lawyer at KPMG Law Firm, and the Head of Healthcare & Life Science at KPMG in Taiwan. He has over 20 years of experience in medical practice and had been a member of IRB, Barnes-Jewish Medical Center and School of Medicine, Washington University in St. Louis, USA.

He has dedicated in various professional areas, especially in government, healthcare, biotechnology and pharmaceutics, such as M&A and IPO. He also led and accomplished the first sale-leaseback transaction of medical institutes in Asia as Chief Counsel. Meanwhile, Jarret provides advisory services of healthcare and biopharmaceutics issues, such as clinical trial, licensing, drug pricing, reimbursement, malpractice, regulatory compliance, etc.
 

Speech title & Synopsis

Investment Trends in Digital Health

Taiwan has the specific niches on digital health, by the competitive advantage of ICT hardware & semiconductor manufacturing, and high quality of medical care system. According to the KPMG “2022 Healthcare and Life Sciences Investment Outlook Survey,” the deal volume of healthcare and life-sciences is expected to sustain a steady pace in 2022. More than half of healthcare and life sciences PE investors plan to do at least 10% more deals than in 2021. Valuation growth is expected in biopharma (65%), medical devices (75%), pharma services (75%), and healthcare IT (70%). Besides, tele-health targets were the top choice cited by investors for 2022 health IT deals. The increased use of telehealth has a spill-over effect and broad investment interest across all areas of healthcare IT. Therefore, we will elaborate the investment trends in digital health from both Taiwan and global aspects.